Helen of Troy Limited (HELE) 10-Q 8 Jan 24 2024 Q3 Quarterly report Financial data

Cover page

Cover page - shares	9 Months Ended
	Nov. 30, 2023	Dec. 28, 2023
Entity Addresses [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Nov. 30, 2023
Document Transition Report	false
Entity File Number	001-14669
Entity Registrant Name	HELEN OF TROY LIMITED
Entity Incorporation, State or Country Code	D0
Entity Tax Identification Number	74-2692550
Entity Address, Address Line One	1 Helen of Troy Plaza
Entity Address, City or Town	El Paso
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	79912
City Area Code	915
Local Phone Number	225-8000
Title of 12(b) Security	Common Shares, $0.10 par value per share
Trading Symbol	HELE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		23,746,423
Entity Central Index Key	0000916789
Current Fiscal Year End Date	--02-28
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false
Other Address
Entity Addresses [Line Items]
Entity Address, Address Line One	Clarendon House
Entity Address, Address Line Two	2 Church Street
Entity Address, City or Town	Hamilton
Entity Address, Country	BM

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Nov. 30, 2023	Feb. 28, 2023
Assets, current:
Cash and cash equivalents	$ 25,247	$ 29,073
Receivables, less allowances of $6,879 and $1,678	463,323	377,604
Inventory	426,026	455,485
Prepaid expenses and other current assets	29,535	24,721
Income taxes receivable	12,307	5,158
Total assets, current	956,438	892,041
Property and equipment, net of accumulated depreciation of $162,207 and $178,961	335,302	351,793
Goodwill	1,066,730	1,066,479
Other intangible assets, net of accumulated amortization of $182,434 and $168,574	541,064	553,883
Operating lease assets	37,930	38,751
Deferred tax assets, net	2,972	2,781
Other assets	11,850	7,987
Total assets	2,952,286	2,913,715
Liabilities, current:
Accounts payable	293,050	190,598
Accrued expenses and other current liabilities	231,516	200,718
Income taxes payable	12,915	14,778
Long-term debt, current maturities	6,235	6,064
Total liabilities, current	543,716	412,158
Long-term debt, excluding current maturities	729,413	928,348
Lease liabilities, non-current	39,256	42,672
Deferred tax liabilities, net	40,803	28,048
Other liabilities, non-current	12,820	13,678
Total liabilities	1,366,008	1,424,904
Commitments and contingencies
Stockholders' equity:
Cumulative preferred stock, non-voting, $1.00 par. Authorized 2,000,000 shares; none issued	0	0
Common stock, $0.10 par. Authorized 50,000,000 shares; 23,744,593 and 23,994,405 shares issued and outstanding	2,374	2,399
Additional paid in capital	340,351	317,277
Accumulated other comprehensive income	2,058	4,947
Retained earnings	1,241,495	1,164,188
Total stockholders' equity	1,586,278	1,488,811
Total liabilities and stockholders' equity	$ 2,952,286	$ 2,913,715

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Nov. 30, 2023	Feb. 28, 2023
Statement of Financial Position [Abstract]
Allowance on receivables	$ 6,879	$ 1,678
Property and equipment, accumulated depreciation	162,207	178,961
Other intangible assets, accumulated amortization	$ 182,434	$ 168,574
Cumulative preferred stock, nonvoting, par value (in dollars per share)	$ 1	$ 1
Cumulative preferred stock, non-voting, authorized shares (in shares)	2,000,000	2,000,000
Cumulative preferred stock, non-voting, issued shares (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, authorized shares (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	23,744,593	23,994,405
Common stock, shares outstanding (in shares)	23,744,593	23,994,405

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022
Income Statement [Abstract]
Sales revenue, net	$ 549,614	$ 558,606	$ 1,515,849	$ 1,588,084
Cost of goods sold	285,833	301,930	806,784	898,791
Gross profit	263,781	256,676	709,065	689,293
Selling, general and administrative expense (“SG&A”)	152,964	169,020	499,790	515,974
Restructuring charges	3,890	10,463	14,862	15,241
Operating income	106,927	77,193	194,413	158,078
Non-operating income, net	180	5	465	185
Interest expense	12,859	13,149	40,565	26,688
Income before income tax	94,248	64,049	154,313	131,575
Income tax expense	18,350	12,223	28,453	24,482
Net income	$ 75,898	$ 51,826	$ 125,860	$ 107,093
Earnings per share (“EPS”):
Basic (in dollars per share)	$ 3.20	$ 2.16	$ 5.27	$ 4.47
Diluted (in dollars per share)	$ 3.19	$ 2.15	$ 5.25	$ 4.45
Weighted average shares used in computing EPS:
Basic (in shares)	23,743	23,991	23,903	23,942
Diluted (in shares)	23,813	24,078	23,996	24,086

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 75,898	$ 51,826	$ 125,860	$ 107,093
Other comprehensive (loss) income, net of tax:
Cash flow hedge activity - interest rate swaps	(1,686)	995	(2,010)	4,502
Cash flow hedge activity - foreign currency contracts	58	(4,056)	(879)	(565)
Total other comprehensive (loss) income, net of tax	(1,628)	(3,061)	(2,889)	3,937
Comprehensive income	$ 74,270	$ 48,765	$ 122,971	$ 111,030

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income	Retained Earnings
Beginning balance (in shares) at Feb. 28, 2022		23,800
Beginning balance at Feb. 28, 2022	$ 1,327,339	$ 2,380	$ 303,740	$ 202	$ 1,021,017
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	24,595				24,595
Other comprehensive income, net of tax	3,159			3,159
Exercise of stock options (in shares)		8
Exercise of stock options	659	$ 1	658
Issuance and settlement of restricted stock (in shares)		235
Issuance and settlement of restricted stock	0	$ 24	(24)
Issuance of common stock related to stock purchase plan (in shares)		13
Issuance of common stock related to stock purchase plan	2,275	$ 1	2,274
Common stock repurchased and retired (in shares)		(89)
Common stock repurchased and retired	(18,224)	$ (9)	(18,113)		(102)
Share-based compensation	16,619		16,619
Ending balance (in shares) at May. 31, 2022		23,967
Ending balance at May. 31, 2022	1,356,422	$ 2,397	305,154	3,361	1,045,510
Beginning balance (in shares) at Feb. 28, 2022		23,800
Beginning balance at Feb. 28, 2022	1,327,339	$ 2,380	303,740	202	1,021,017
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income, net of tax	3,937
Ending balance (in shares) at Nov. 30, 2022		23,991
Ending balance at Nov. 30, 2022	1,457,073	$ 2,399	322,527	4,139	1,128,008
Beginning balance (in shares) at May. 31, 2022		23,967
Beginning balance at May. 31, 2022	1,356,422	$ 2,397	305,154	3,361	1,045,510
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	30,672				30,672
Other comprehensive income, net of tax	3,839			3,839
Issuance and settlement of restricted stock (in shares)		2
Issuance and settlement of restricted stock	(1)		(1)
Common stock repurchased and retired	(81)		(81)
Share-based compensation	7,495		7,495
Ending balance (in shares) at Aug. 31, 2022		23,969
Ending balance at Aug. 31, 2022	1,398,346	$ 2,397	312,567	7,200	1,076,182
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	51,826				51,826
Other comprehensive income, net of tax	(3,061)			(3,061)
Issuance and settlement of restricted stock (in shares)		3
Issuance and settlement of restricted stock	0
Issuance of common stock related to stock purchase plan (in shares)		20
Issuance of common stock related to stock purchase plan	2,066	$ 2	2,064
Common stock repurchased and retired (in shares)		(1)
Common stock repurchased and retired	(45)		(45)
Share-based compensation	7,941		7,941
Ending balance (in shares) at Nov. 30, 2022		23,991
Ending balance at Nov. 30, 2022	1,457,073	$ 2,399	322,527	4,139	1,128,008
Beginning balance (in shares) at Feb. 28, 2023		23,994
Beginning balance at Feb. 28, 2023	1,488,811	$ 2,399	317,277	4,947	1,164,188
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	22,581				22,581
Other comprehensive income, net of tax	(3,715)			(3,715)
Exercise of stock options (in shares)		5
Exercise of stock options	212	$ 1	211
Issuance and settlement of restricted stock (in shares)		120
Issuance and settlement of restricted stock	0	$ 12	(12)
Issuance of common stock related to stock purchase plan (in shares)		23
Issuance of common stock related to stock purchase plan	2,168	$ 2	2,166
Common stock repurchased and retired (in shares)		(45)
Common stock repurchased and retired	(4,446)	$ (4)	(4,442)
Share-based compensation	9,297		9,297
Ending balance (in shares) at May. 31, 2023		24,097
Ending balance at May. 31, 2023	1,514,908	$ 2,410	324,497	1,232	1,186,769
Beginning balance (in shares) at Feb. 28, 2023		23,994
Beginning balance at Feb. 28, 2023	1,488,811	$ 2,399	317,277	4,947	1,164,188
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income, net of tax	(2,889)
Ending balance (in shares) at Nov. 30, 2023		23,744
Ending balance at Nov. 30, 2023	1,586,278	$ 2,374	340,351	2,058	1,241,495
Beginning balance (in shares) at May. 31, 2023		24,097
Beginning balance at May. 31, 2023	1,514,908	$ 2,410	324,497	1,232	1,186,769
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	27,381				27,381
Other comprehensive income, net of tax	2,454			2,454
Issuance and settlement of restricted stock (in shares)		4
Issuance and settlement of restricted stock	0
Common stock repurchased and retired (in shares)		(382)
Common stock repurchased and retired	(50,089)	$ (38)	(1,499)		(48,552)
Share-based compensation	7,229		7,229
Ending balance (in shares) at Aug. 31, 2023		23,719
Ending balance at Aug. 31, 2023	1,501,883	$ 2,372	330,227	3,686	1,165,598
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	75,898				75,898
Other comprehensive income, net of tax	(1,628)			(1,628)
Exercise of stock options (in shares)		1
Exercise of stock options	53		53
Issuance and settlement of restricted stock (in shares)		8
Issuance and settlement of restricted stock	0	$ 1	(1)
Issuance of common stock related to stock purchase plan (in shares)		19
Issuance of common stock related to stock purchase plan	1,799	$ 2	1,797
Common stock repurchased and retired (in shares)		(3)
Common stock repurchased and retired	(306)	$ (1)	(304)		(1)
Share-based compensation	8,579		8,579
Ending balance (in shares) at Nov. 30, 2023		23,744
Ending balance at Nov. 30, 2023	$ 1,586,278	$ 2,374	$ 340,351	$ 2,058	$ 1,241,495

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Cash provided by operating activities:
Net income	$ 125,860	$ 107,093
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	37,037	33,330
Amortization of financing costs	923	792
Non-cash operating lease expense	7,537	7,558
Provision for credit losses	5,421	1,373
Non-cash share-based compensation	25,105	32,055
Gain on sale of distribution and office facilities	(34,190)	0
Gain on sale of Personal Care business	0	(1,336)
Gain on the sale or disposal of property and equipment	(326)	5
Deferred income taxes and tax credits	13,430	1,479
Changes in operating capital, net of effects of acquisitions of businesses:
Receivables	(87,575)	(45,714)
Inventory	29,459	28,996
Prepaid expenses and other current assets	(5,507)	3,926
Other assets and liabilities, net	(1,082)	(1,113)
Accounts payable	102,295	(78,128)
Accrued expenses and other current liabilities	22,484	(22,945)
Accrued income taxes	(8,412)	(17,848)
Net cash provided by operating activities	232,459	49,523
Cash provided (used) by investing activities:
Capital and intangible asset expenditures	(29,681)	(146,194)
Net payments to acquire businesses, net of cash acquired	0	(146,342)
Payments for purchases of U.S. Treasury Bills	(7,373)	0
Proceeds from sale of distribution and office facilities	49,456	0
Proceeds from sale of Personal Care business	0	1,804
Proceeds from the sale of property and equipment	1,609	63
Net cash provided (used) by investing activities	14,011	(290,669)
Cash (used) provided by financing activities:
Proceeds from revolving loans	635,800	633,500
Repayment of revolving loans	(830,800)	(613,000)
Proceeds from term loans	0	250,000
Repayment of long-term debt	(4,687)	(3,462)
Payment of financing costs	0	(586)
Proceeds from share issuances under share-based compensation plans	4,232	5,000
Payments for repurchases of common stock	(54,841)	(18,350)
Net cash (used) provided by financing activities	(250,296)	253,102
Net (decrease) increase in cash and cash equivalents	(3,826)	11,956
Cash and cash equivalents, beginning balance	29,073	33,381
Cash and cash equivalents, ending balance	25,247	45,337
Supplemental non-cash investing activity:
Capital expenditures included in accounts payable	$ 2,439	$ 11,038

Basis of Presentation and Relat

Basis of Presentation and Related Information	9 Months Ended
	Nov. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Related Information	Note 1 - Basis of Presentation and Related Information Corporate Overview The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly our consolidated financial position as of November 30, 2023 and February 28, 2023, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K for the fiscal year ended February 28, 2023 (“Form 10-K”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). When used in these notes, unless otherwise indicated or the context suggests otherwise, references to “the Company”, “our Company”, “Helen of Troy”, “we”, “us”, or “our” refer to Helen of Troy Limited and its subsidiaries, which are all wholly-owned. We refer to our common shares, par value $0.10 per share, as “common stock.” References to “the FASB” refer to the Financial Accounting Standards Board. References to “GAAP” refer to accounting principles generally accepted in the United States of America (the “U.S.”). References to “ASU” refer to the codification of GAAP in the Accounting Standards Updates issued by the FASB. References to “ASC” refer to the codification of GAAP in the Accounting Standards Codification issued by the FASB. We incorporated as Helen of Troy Corporation in Texas in 1968 and were reorganized as Helen of Troy Limited in Bermuda in 1994. We are a leading consumer products company offering creative products and solutions for our customers through a diversified portfolio of brands. As of November 30, 2023, we operated two reportable segments: Home & Outdoor and Beauty & Wellness. During the fourth quarter of fiscal 2023, we made changes to the structure of our organization in connection with our global restructuring plan (as further described below and in Note 8) that resulted in our previous Health & Wellness and Beauty operating segments being combined into a single reportable segment, which is referred to herein as “Beauty & Wellness.” In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our Chief Executive Officer (“CEO”), our chief operating decision maker, assesses performance and allocates resources. We believe that these changes better align internal resources and external go to market activities in order to create a more efficient and effective organizational structure. There were no changes to the products or brands included within our Home & Outdoor reportable segment as part of these organizational changes nor to the way in which our CEO assesses performance and allocates resources for the Home & Outdoor segment. As a result of these changes, our disclosures reflect two reportable segments, Home & Outdoor and Beauty & Wellness. Comparative prior period segment information in this report has been recast to conform to this change in our reportable segments. Our external reportable segments will continue to align with our internal reporting to enable users of the financial statements to better understand our performance, better assess our future net cash flows, and make more informed judgments about the Company as a whole. Our Home & Outdoor segment provides a broad range of outstanding world-class brands that help consumers enjoy an outdoor lifestyle and make everyday living better. Our innovative products for home activities include food preparation, cooking, cleaning, organization, and beverage service. Our outdoor performance range includes hydration products, backpacks, and travel gear to ease your journey and inspire your next adventure. The Beauty & Wellness segment provides consumers with a broad range of outstanding world-class brands for beauty and wellness. In Beauty, we deliver innovation through products such as hair styling appliances, grooming tools, and liquid-, solid-, and powder-based personal care products that help make everyone look and feel more beautiful. On the Wellness side, we are there when you need us most with highly regarded humidifiers, thermometers, water and air purifiers, heaters, and fans. Our business is seasonal due to different calendar events, holidays and seasonal weather and illness patterns. Our fiscal reporting period ends on the last day in February. Historically, our highest sales volume and operating income occur in our third fiscal quarter ending November 30th. We purchase our products from unaffiliated manufacturers, most of which are located in China, Mexico, Vietnam and the U.S. During the second quarter of fiscal 2023, we focused on developing a global restructuring plan intended to expand operating margins through initiatives designed to improve efficiency and reduce costs (referred to as “Project Pegasus”). See Note 8 for additional information. On April 22, 2022, we completed the acquisition of Recipe Products Ltd., a producer of innovative prestige hair care products for all types of curly and wavy hair under the Curlsmith brand (“Curlsmith”). The total purchase consideration was $147.9 million in cash, net of a final net working capital adjustment and cash acquired. The Curlsmith brand and products were added to the Beauty & Wellness segment. See Note 4 for additional information. During fiscal 2022 and fiscal 2023, we divested certain assets within our Beauty & Wellness segment's mass channel personal care business, which included liquid, powder and aerosol products under brands such as Pert, Brut, Sure and Infusium (“Personal Care”). On June 7, 2021, we completed the sale of our North America Personal Care business to HRB Brands LLC, for $44.7 million in cash and recognized a gain on the sale in SG&A totaling $0.5 million. On March 25, 2022, we completed the sale of the Latin America and Caribbean Personal Care business to HRB Brands LLC, for $1.8 million in cash and recognized a gain on the sale in SG&A totaling $1.3 million. Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include all of our subsidiaries. Our condensed consolidated financial statements are prepared in U.S. Dollars. All intercompany balances and transactions are eliminated in consolidation. The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results may differ materially from those estimates. Reclassifications We have reclassified or combined certain amounts in the prior year's accompanying footnotes to conform with the current year's presentation.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Nov. 30, 2023
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Note 2 - New Accounting Pronouncements Except for the changes discussed below, there have been no changes in the information provided in our Form 10-K. Adopted In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations , which requires a buyer in a supplier finance program to disclose qualitative and quantitative information about its program to allow a user of the financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. The amendments in ASU 2022-04 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with the exception for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The guidance should be applied retrospectively, except for the amendment on rollforward information, which should be applied prospectively. This ASU was effective for us in the first quarter of fiscal 2024, with the exception of the amendment on rollforward information, which will be effective for us in our Form 10-K for fiscal 2025. We adopted this ASU during the first quarter of fiscal 2024 and the adoption did not have an impact on our consolidated financial statement disclosures. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers . Prior to the issuance of this guidance, contract assets and contract liabilities were recognized by the acquirer at fair value on the acquisition date. The amendments in ASU 2021-08 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, and should be applied prospectively to acquisitions occurring on or after the effective date. We adopted this ASU during the first quarter of fiscal 2024 and the adoption did not have an impact on our consolidated financial statements. Not Yet Adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. This ASU will be effective for our Form 10-K for fiscal 2025 and our Form 10-Q for the first quarter of fiscal 2026. We are currently evaluating the impact this ASU may have on our consolidated financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied prospectively; however, retrospective application is also permitted. This ASU will be effective for our Form 10-K for fiscal 2026. We are currently evaluating the impact this ASU may have on our consolidated financial statement disclosures.

Gain on Sale of Distribution an

Gain on Sale of Distribution and Office Facilities	9 Months Ended
	Nov. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Gain on Sale of Distribution and Office Facilities	Note 3 - Gain on Sale of Distribution and Office Facilities On September 28, 2023, we completed the sale of our distribution and office facilities in El Paso, Texas for a sales price of $50.6 million, less transaction costs of $1.1 million. Concurrently, we entered into an

Acquisition of Curlsmith

Acquisition of Curlsmith	9 Months Ended
	Nov. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisition of Curlsmith	Note 4 - Acquisition of Curlsmith On April 22, 2022, we completed the acquisition of Recipe Products Ltd., a producer of innovative prestige hair care products for all types of curly and wavy hair under the Curlsmith brand. Curlsmith's products are a category leader in the prestige market for curly hair and include conditioners, shampoos and co-washes purposefully designed for the unique joys and challenges of all types of curls and textured hair. The Curlsmith brand and products were added to the Beauty & Wellness segment. The total purchase consideration was $147.9 million in cash, net of a final net working capital adjustment of $2.1 million and cash acquired. The acquisition was funded with cash on hand and borrowings under our existing revolving credit facility. We incurred pre-tax acquisition-related expenses of $2.7 million during the nine months ended November 30, 2022, which were recognized in SG&A within our condensed consolidated statement of income. We accounted for the acquisition as a purchase of a business and recorded the excess of the purchase price over the estimated fair value of the assets acquired and liabilities assumed as goodwill. The goodwill recognized is attributable primarily to expected synergies including leveraging our Beauty & Wellness segment's existing marketing and sales structure, as well as our global sourcing, distribution, shared service, and international go-to-market capabilities. The goodwill is not expected to be deductible for income tax purposes. We have determined the appropriate fair values of the acquired intangible assets and completed our analysis of the economic lives of the assets acquired. We assigned $21.0 million to trade names and are amortizing over a 20 year expected life. We assigned $12.0 million to customer relationships and are amortizing over a 19.5 year expected life, based on historical attrition rates. During fiscal 2023, we made adjustments to provisional asset and liability balances, which resulted in a corresponding net increase to goodwill of $0.1 million. We also finalized the net working capital adjustment during fiscal 2023, which resulted in a $1.8 million reduction to the total purchase consideration and goodwill. During the first quarter of fiscal 2024, we made final adjustments to provisional liability balances, which resulted in a corresponding increase to goodwill of $0.3 million. The following table presents the estimated fair values of assets acquired and liabilities assumed at the acquisition date: (in thousands) Assets: Receivables $ 4,211 Inventory 7,890 Prepaid expenses and other current assets 119 Property and equipment 212 Goodwill 117,108 Trade names - definite 21,000 Customer relationships - definite 12,000 Deferred tax assets, net 360 Total assets 162,900 Liabilities: Accounts payable 1,401 Accrued expenses and other current liabilities 2,813 Income taxes payable 2,572 Deferred tax liabilities, net 8,187 Total liabilities 14,973 Net assets recorded $ 147,927 Both the fair value and gross contractual amount of receivables acquired was $4.2 million, as an immaterial amount was expected to be uncollectible. The impact of the acquisition of Curlsmith on our condensed consolidated statements of income for the periods presented was as follows: (in thousands, except earnings per share data) Three Months Ended November 30, 2022 (1) Nine Months Ended November 30, 2022 (1) (2) Sales revenue, net $ 13,091 $ 26,544 Net income 2,077 3,953 EPS: Basic $ 0.09 $ 0.17 Diluted $ 0.09 $ 0.16 (1) Net income and EPS amounts include allocations for corporate expenses, interest expense and income tax expense. (2) Represents approximately thirty-two weeks of operating results from Curlsmith, acquired April 22, 2022. The following supplemental unaudited pro forma information presents our financial results as if the acquisition of Curlsmith had occurred on March 1, 2021. This supplemental pro forma information has been prepared for comparative purposes and does not necessarily indicate what may have occurred if the acquisition had been completed on March 1, 2021, and this information is not intended to be indicative of future results. (in thousands, except earnings per share data) Three Months Ended November 30, 2022 Nine Months Ended Sales revenue, net $ 558,606 $ 1,595,176 Net income 51,826 109,006 EPS: Basic $ 2.16 $ 4.55 Diluted $ 2.15 $ 4.53

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Nov. 30, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Note 5 - Accrued Expenses and Other Current Liabilities A summary of accrued expenses and other current liabilities was as follows: (in thousands) November 30, 2023 February 28, 2023 Accrued compensation, benefits and payroll taxes $ 37,905 $ 17,380 Accrued sales discounts and allowances 60,267 63,881 Accrued sales returns 25,584 28,498 Accrued advertising 43,224 36,931 Other 64,536 54,028 Total accrued expenses and other current liabilities $ 231,516 $ 200,718

Share-Based Compensation Plans

Share-Based Compensation Plans	9 Months Ended
	Nov. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation Plans	Note 6 - Share-Based Compensation Plans As part of our compensation structure, we grant share-based compensation awards to certain employees and non-employee members of our Board of Directors during the fiscal year. These awards may be subject to attainment of certain service conditions, performance conditions and/or market conditions. During the first quarter of fiscal 2024, we granted 94,807 service condition awards (“Service Condition Awards”) with a weighted average grant date fair value of $110.85. Additionally, we granted 252,522 performance-based awards during the first quarter of fiscal 2024, of which 126,318 contained performance conditions (“Performance Condition Awards”) and 126,204 contained market conditions (“Market Condition Awards”), with weighted average grant date fair values of $110.85 and $80.50, respectively. Refer to our Form 10-K for further information on the Company's share-based compensation plans. We recorded share-based compensation expense in SG&A as follows: Three Months Ended November 30, Nine Months Ended (in thousands) 2023 2022 2023 2022 Directors stock compensation $ 197 $ 197 $ 590 $ 592 Service Condition Awards 3,160 2,211 9,358 7,488 Performance Condition Awards 1,170 3,252 4,306 17,293 Market Condition Awards 3,458 1,793 9,647 5,620 Employee stock purchase plan 594 488 1,204 1,062 Share-based compensation expense 8,579 7,941 25,105 32,055 Less income tax benefits (532) (474) (1,558) (2,128) Share-based compensation expense, net of income tax benefits $ 8,047 $ 7,467 $ 23,547 $ 29,927 Unrecognized Share-Based Compensation Expense As of November 30, 2023, our total unrecognized share-based compensation for all awards was $25.8 million, which will be recognized over a weighted average amortization period of 1.9 years. The total unrecognized share-based compensation reflects an estimate of target achievement for Performance Condition Awards granted during the first quarter of fiscal 2024, and an estimate of zero percent of target achievement for Performance Condition Awards granted in fiscal 2023 and fiscal 2022.

Repurchases of Common Stock

Repurchases of Common Stock	9 Months Ended
	Nov. 30, 2023
Equity [Abstract]
Repurchases of Common Stock	Note 7 - Repurchases of Common Stock In August 2021, our Board of Directors authorized the repurchase of up to $500 million of our outstanding common stock. The authorization became effective August 25, 2021, for a period of three years, and replaced our former repurchase authorization. As of November 30, 2023, our repurchase authorization allowed for the purchase of $348.8 million of common stock. Our current equity-based compensation plans include provisions that allow for the “net exercise” of share-settled awards by all plan participants. In a net exercise, any required payroll taxes, federal withholding taxes and exercise price of the shares due from the option or other share-based award holders are settled by having the holder tender back to us a number of shares at fair value equal to the amounts due. Net exercises are treated as purchases and retirements of shares. The following table summarizes our share repurchase activity for the periods shown: Three Months Ended November 30, Nine Months Ended November 30, (in thousands, except share and per share data) 2023 2022 2023 2022 Common stock repurchased on the open market: Number of shares — — 381,200 — Aggregate value of shares $ — $ — $ 50,006 $ — Average price per share $ — $ — $ 131.18 $ — Common stock received in connection with share-based compensation: Number of shares 2,701 382 48,098 90,341 Aggregate value of shares $ 306 $ 45 $ 4,835 $ 18,350 Average price per share $ 113.31 $ 117.44 $ 100.51 $ 203.12

Restructuring Plan

Restructuring Plan	9 Months Ended
	Nov. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring Plan	Note 8 - Restructuring Plan During the second quarter of fiscal 2023, we focused on developing Project Pegasus, a global restructuring plan intended to expand operating margins through initiatives designed to improve efficiency and reduce costs. Project Pegasus includes initiatives to further optimize our brand portfolio, streamline and simplify the organization, accelerate cost of goods savings projects, enhance the efficiency of our supply chain network, optimize our indirect spending, and improve our cash flow and working capital, as well as other activities. We anticipate these initiatives will create operating efficiencies, as well as provide a platform to fund future growth investments. During the fourth quarter of fiscal 2023, we made changes to the structure of our organization in connection with Project Pegasus that resulted in our previous Health & Wellness and Beauty operating segments being combined into a single reportable segment, which is referred to herein as “Beauty & Wellness.” In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our CEO, our chief operating decision maker, assesses performance and allocates resources. We believe that these changes better align internal resources and external go to market activities in order to create a more efficient and effective organizational structure. There were no changes to the products or brands included within our Home & Outdoor reportable segment as part of these organizational changes. As part of our initiative focused on streamlining and simplifying the organization, we made further changes to the structure of our organization, during the fourth quarter of fiscal 2023, which include the creation of a North America Regional Market Organization (“RMO”) responsible for sales and go to market strategies for all categories and channels in the U.S. and Canada, and further centralization of certain functions under shared services, particularly in operations and finance to better support our business segments and RMOs. This new structure, inclusive of the organizational structure changes described above resulting in the reportable segment change, will reduce the size of our global workforce by approximately 10%. The majority of these role reductions were completed by March 1, 2023. We believe that these changes better focus business segment resources on brand development, consumer-centric innovation and marketing, the RMOs on sales and go to market strategies, and shared services on their respective areas of expertise while also creating a more efficient and effective organizational structure. During the second quarter of fiscal 2024, we announced plans to geographically consolidate the U.S. Beauty business, currently located in El Paso, Texas, and Irvine, California, and co-locate it with our Wellness business in the Boston, Massachusetts area. This geographical consolidation and relocation is the next step in our initiative to streamline and simplify the organization and it is expected to be completed during fiscal 2025. We expect these changes will enable a greater opportunity to capture synergies and enhance collaboration and innovation within the Beauty & Wellness segment. As previously disclosed, we continue to have the following expectations regarding Project Pegasus charges: • Total one-time pre-tax restructuring charges of approximately $60 million to $65 million over the duration of the plan, expected to be completed during fiscal 2025. • Pre-tax restructuring charges to be comprised of approximately $22 million to $25 million of severance and employee related costs, $30 million of professional fees, $5 million of contract termination costs, and $3 million to $5 million of other exit and disposal costs. • All of our operating segments and shared services will be impacted by the plan and pre-tax restructuring charges include approximately $17 million to $19 million in Home & Outdoor and $43 million to $46 million in Beauty & Wellness. • Pre-tax restructuring charges represent primarily cash expenditures, which are expected to be substantially paid by the end of fiscal 2025. We also continue to have the following expectations regarding Project Pegasus savings: • Targeted annualized pre-tax operating profit improvements of approximately $75 million to $85 million, which began in fiscal 2024 and we expect to be substantially achieved by the end of fiscal 2026. • Estimated cadence of the recognition of the savings will be approximately 25% in fiscal 2024, approximately 50% in fiscal 2025 and approximately 25% in fiscal 2026. • Total profit improvements to be realized approximately 60% through reduced cost of goods sold and 40% through lower SG&A. During the three and nine month periods ended November 30, 2023, we incurred $3.9 million and $14.9 million, respectively, of pre-tax restructuring costs in connection with Project Pegasus, which were recorded as “Restructuring charges” in the condensed consolidated statements of income. We recognized $10.5 million and $15.2 million of pre-tax restructuring costs during the three and nine month periods ended November 30, 2022, respectively, in connection with Project Pegasus. The following tables summarize restructuring charges recorded as a result of Project Pegasus for the periods presented: Three Months Ended November 30, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 109 $ 2,498 $ 2,607 Professional fees 464 794 1,258 Contract termination — — — Other 10 15 25 Total restructuring charges $ 583 $ 3,307 $ 3,890 Three Months Ended November 30, 2022 (in thousands) Home & Beauty & Total Severance and employee related costs $ 426 $ 749 $ 1,175 Professional fees 4,663 4,511 9,174 Contract termination — — — Other 1 113 114 Total restructuring charges $ 5,090 $ 5,373 $ 10,463 Nine Months Ended November 30, 2023 Total (in thousands) Home & Beauty & Wellness Total Severance and employee related costs $ 680 $ 3,407 $ 4,087 $ 13,540 Professional fees 3,915 5,870 9,785 26,534 Contract termination — 796 796 1,331 Other 49 145 194 819 Total restructuring charges $ 4,644 $ 10,218 $ 14,862 $ 42,224 Nine Months Ended November 30, 2022 (in thousands) Home & Beauty & Total Severance and employee related costs $ 898 $ 3,120 $ 4,018 Professional fees 4,663 4,639 9,302 Contract termination — 1,500 1,500 Other 1 420 421 Total restructuring charges $ 5,562 $ 9,679 $ 15,241 The tables below present a rollforward of our accruals related to Project Pegasus, which are included in accounts payable and accrued expenses and other current liabilities: (in thousands) Balance at February 28, 2023 Charges Payments Balance at November 30, 2023 Severance and employee related costs $ 3,173 $ 4,087 $ (3,758) $ 3,502 Professional fees 3,201 9,785 (12,559) 427 Contract termination 160 796 (956) — Other 34 194 (228) — Total $ 6,568 $ 14,862 $ (17,501) $ 3,929 (in thousands) Balance at February 28, 2022 Charges Payments Balance at November 30, 2022 Severance and employee related costs $ — $ 4,018 $ (2,805) $ 1,213 Professional fees — 9,302 (2,196) 7,106 Contract termination — 1,500 — 1,500 Other — 421 (414) 7 Total $ — $ 15,241 $ (5,415) $ 9,826

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Nov. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 - Commitments and Contingencies Legal Matters We are involved in various legal claims and proceedings in the normal course of operations. We believe the outcome of these matters will not have a material adverse effect on our consolidated financial position, results of operations or liquidity, except as described below. On December 23, 2021, Brita LP filed a complaint against Kaz USA, Inc. and Helen of Troy Limited in the United States District Court for the Western District of Texas (the “Patent Litigation”), alleging patent infringement by the Company relating to its PUR gravity-fed water filtration systems. In the Patent Litigation, Brita LP seeks monetary damages and injunctive relief relating to the alleged infringement. Brita LP simultaneously filed a complaint with the United States International Trade Commission (“ITC”) against Kaz USA, Inc., Helen of Troy Limited and five other unrelated companies that sell water filtration systems (the “ITC Action”). The complaint in the ITC Action also alleges patent infringement by the Company with respect to a limited set of PUR gravity-fed water filtration systems. In the ITC Action, Brita LP requested the ITC to initiate an unfair import investigation relating to such filtration systems. This action seeks injunctive relief to prevent entry of certain accused PUR products (and certain other products) into the U.S. and cessation of marketing and sales of existing inventory that is already in the U.S. On January 25, 2022, the ITC instituted the investigation requested by the ITC Action. Discovery closed in the ITC Action in May 2022, and approximately half of the originally identified PUR gravity-fed water filters were removed from the case and are no longer included in the ITC Action. In August 2022, the parties participated in the evidentiary hearing, with additional supplemental hearings in October 2022. On February 28, 2023, the ITC issued an Initial Determination in the ITC Action, tentatively ruling against Kaz USA, Inc. and the other unrelated respondents. The ITC has a guaranteed review process, and thus all respondents, including Kaz USA, Inc., filed a petition with the ITC for a full review of the Initial Determination. On September 19, 2023, the ITC issued its Final Determination in the Company’s favor. The ITC determined there was no violation by the Company and terminated the investigation. Brita LP is appealing the ITC's decision to the Federal Circuit (“CAFC Appeal”) and filed its Notice of Appeal on October 24, 2023. The Company intervened in the CAFC Appeal, but as of the filing date of this Form 10-Q, no hearings have been scheduled. The Patent Litigation remains stayed for the time being. We cannot predict the outcome of these legal proceedings, the amount or range of any potential loss, when the proceedings will be resolved, or customer acceptance of any replacement water filter. Litigation is inherently unpredictable, and the resolution or disposition of these proceedings could, if adversely determined, have a material and adverse impact on our financial position and results of operations. Regulatory Matters Our operations are subject to national, state, local, and provincial jurisdictions’ environmental, health and safety laws and regulations and industry-specific product certifications. Many of the products we sell are subject to product safety laws and regulations in various jurisdictions. These laws and regulations specify the maximum allowable levels of certain materials that may be contained in our products, provide statutory prohibitions against misbranded and adulterated products, establish ingredients and manufacturing procedures for certain products, specify product safety testing requirements, and set product identification, labeling and claim requirements. Some of our product lines are subject to product identification, labeling and claim requirements, which are monitored and enforced by regulatory agencies, such as the U.S. Environmental Protection Agency (the “EPA”), U.S. Customs and Border Protection, the U.S. Food and Drug Administration, and the U.S. Consumer Product Safety Commission. During fiscal 2022, we were in discussions with the EPA regarding the compliance of packaging claims on certain of our products in the air and water filtration categories and a limited subset of humidifier products within the Beauty & Wellness segment that are sold in the U.S. The EPA did not raise any product quality, safety or performance issues. As a result of these packaging compliance discussions, we voluntarily implemented a temporary stop shipment action on the impacted products as we worked with the EPA towards an expedient resolution. We resumed normalized levels of shipping of the affected inventory during fiscal 2022 and we completed the repackaging and relabeling of our existing inventory of impacted products during fiscal 2023. Additionally, as a result of continuing dialogue with the EPA, we executed further repackaging and relabeling plans on certain additional humidifier products and certain additional air filtration products, which were also completed during fiscal 2023. Although we are not aware of any fines or penalties imposed against us by the EPA related to this matter, there can be no assurances that such fines or penalties will not be imposed in the future. We recorded charges to cost of goods sold to write-off obsolete packaging for the affected products in our inventory on-hand and in-transit. We have also incurred additional compliance costs comprised of obsolete packaging, storage and other charges from vendors, which were recognized in cost of goods sold and incremental warehouse storage costs and legal fees, which were recognized in SG&A. We refer to these charges as “EPA compliance costs.” The following table provides a summary of EPA compliance costs incurred during the periods presented: Three Months Ended November 30, Nine Months Ended November 30, (in thousands) 2023 2022 2023 2022 Cost of goods sold $ — $ 370 $ — $ 16,928 1 SG&A — 1,733 — 5,173 Total EPA compliance costs $ — $ 2,103 $ — $ 22,101 (1) Includes a $4.4 million charge to write-off the obsolete packaging for the affected additional humidifier products and affected additional air filtration products in our inventory on-hand and in-transit as of the end of the first quarter of fiscal 2023. In addition, we incurred and capitalized into inventory costs to repackage a portion of our existing inventory of the affected products beginning in the second quarter of fiscal 2022 through completion of the repackaging in the third quarter of fiscal 2023. For additional information refer to Part I, Item 2., “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” including “EPA Compliance Costs”. Weather-Related Incident On March 30, 2022, a third-party facility that we utilized for inventory storage incurred severe damage from a weather-related incident. The inventory that was stored at this facility primarily related to our Beauty & Wellness segment. While the inventory was insured, some seasonal inventory and inventory designated for specific customer promotions was not accessible and subsequently determined to be damaged, and as a result, unfavorably impacted our net sales revenue during the first quarter of fiscal 2023. As a result of the damages to the inventory stored at the facility, we recorded a charge to write-off the damaged inventory totaling $34.4 million during the first quarter of fiscal 2023. These charges were fully offset by probable insurance recoveries of $34.4 million also recorded during the first quarter of fiscal 2023, which represented anticipated insurance proceeds, not to exceed the amount of the associated losses, for which receipt was deemed probable. The charges for the damaged inventory and the expected insurance recoveries are included in cost of goods sold in our condensed consolidated statement of income for the nine months ended November 30, 2022. During the third quarter of fiscal 2023, we received proceeds of $34.5 million from our insurance carriers related to this incident which were included in cash flows from operating activities in our condensed consolidated statement of cash flows for the nine months ended November 30, 2022. The Company also received final confirmation from our insurance carriers during the third quarter of fiscal 2023 of an additional $11.5 million in proceeds, which was collected during December 2022. As a result, during the third quarter of fiscal 2023, the Company recorded a gain of $9.7 million, net of costs incurred to dispose of the inventory, as a reduction of SG&A expense in our condensed consolidated statement of income.

Long-Term Debt

Long-Term Debt	9 Months Ended
	Nov. 30, 2023
Debt Disclosure [Abstract]
Long-Term Debt	Note 10 - Long-Term Debt A summary of our long-term debt follows: (in thousands) November 30, 2023 February 28, 2023 Credit Agreement (1): Revolving loans $ 495,000 $ 690,000 Term loans 242,188 246,875 Total borrowings under Credit Agreement 737,188 936,875 Unamortized prepaid financing fees (1,540) (2,463) Total long-term debt 735,648 934,412 Less: current maturities of long-term debt (6,235) (6,064) Long-term debt, excluding current maturities $ 729,413 $ 928,348 (1) The weighted average interest rates on borrowings outstanding under the Credit Agreement (defined below) as of November 30, 2023 and February 28, 2023 were 7.1% and 6.6%, respectively. Capitalized Interest During the three month period ended November 30, 2023, we incurred interest costs totaling $12.9 million, of which none was capitalized, compared to $14.8 million for the same period last year, of which we capitalized $1.7 million as part of property and equipment in connection with the construction of a new distribution facility. During the nine month periods ended November 30, 2023 and November 30, 2022, we incurred interest costs totaling $41.5 million and $30.0 million, respectively, of which we capitalized $0.9 million and $3.3 million, respectively, in connection with the previously mentioned distribution facility. Credit Agreement We have a credit agreement (the “Credit Agreement”) with Bank of America, N.A., as administrative agent, and other lenders that provides for an unsecured total revolving commitment of $1.25 billion and a $300 million accordion, which can be used for term loan commitments. In June 2022, we exercised $250 million of the $300 million accordion under the Credit Agreement and borrowed $250 million as term loans. The proceeds from the term loans were used to repay revolving loans under the Credit Agreement. The term loans are payable at the end of each fiscal quarter in equal installments of 0.625% of the term loans made, which began in the third quarter of fiscal 2023, with the remaining balance due at the maturity date. The maturity date of the term loans and the revolving loans under the Credit Agreement is March 13, 2025. Borrowings under the Credit Agreement bear floating interest at either the Base Rate or Term SOFR (as defined in the Credit Agreement), plus a margin based on the Net Leverage Ratio (as defined in the Credit Agreement) of 0% to 1.0% and 1.0% to 2.0% for Base Rate and Term SOFR borrowings, respectively, plus a credit spread of 0.10% for Term SOFR borrowings. The floating interest rates on our borrowings under the Credit Agreement are hedged with interest rate swaps to effectively fix interest rates on $625 million and $425 million of the outstanding principal balance under the revolving loans as of November 30, 2023 and February 28, 2023, respectively. See Notes 11, 12, and 13 for additional information regarding our interest rate swaps. As of November 30, 2023, the balance of outstanding letters of credit was $15.5 million and the amount available for revolving loans under the Credit Agreement was $739.5 million. Covenants in the Credit Agreement limit the amount of total indebtedness we can incur. As of November 30, 2023, these covenants effectively limited our ability to incur more than $336.2 million of additional debt from all sources, including the Credit Agreement, or $569.6 million in the event a qualified acquisition is consummated. Debt Covenants As of November 30, 2023, we were in compliance with all covenants as defined under the terms of the Credit Agreement.

Fair Value

Fair Value	9 Months Ended
	Nov. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value	Note 11 - Fair Value Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques under the accounting guidance related to fair value measurements are based on observable and unobservable inputs. These inputs are classified into the following hierarchy: Level 1: Quoted prices for identical assets or liabilities in active markets; Level 2: Observable inputs other than quoted prices that are directly or indirectly observable for the asset or liability, including quoted prices for similar assets or liabilities in active markets; quoted prices for similar or identical assets or liabilities in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable; and Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. All of our financial assets and liabilities, except for our investments in U.S. Treasury Bills, are classified as Level 2 because their valuation is dependent on observable inputs and other quoted prices for similar assets or liabilities, or model-derived valuations whose significant value drivers are observable. Our investments in U.S. Treasury Bills are classified as Level 1 because their value is based on quoted prices in active markets for identical assets. The following table presents the fair value of our financial assets and liabilities: Fair Value (in thousands) November 30, 2023 February 28, 2023 Assets: Cash equivalents (money market accounts) $ 2,829 $ 381 U.S. Treasury Bills 7,435 — Interest rate swaps 3,117 5,746 Foreign currency derivatives 204 1,423 Total assets $ 13,585 $ 7,550 Liabilities: Foreign currency derivatives 699 711 Total liabilities $ 699 $ 711 All of our financial assets and liabilities, except for our investments in U.S. Treasury Bills, are measured and recorded at fair value on a recurring basis. Our investments in U.S. Treasury Bills, are recorded at amortized cost. As of November 30, 2023, the current and non-current carrying amounts of our U.S. Treasury Bills were $2.4 million and $5.0 million, respectively, and were included within Prepaid expenses and other current assets and Other assets, respectively, in our condensed consolidated balance sheet. The carrying amounts of cash, accounts payable, accrued expenses and other current liabilities and income taxes payable approximate fair value because of the short maturity of these items. The carrying amounts of receivables approximate fair value due to the effect of the related allowance for credit losses. The carrying amount of our floating rate long-term debt approximates its fair value. Our investments in U.S. Treasury Bills are classified as held-to-maturity because we have the positive intent and ability to hold the securities to maturity. We invest in U.S. Treasury Bills with maturities ranging from one We use derivatives to manage our exposure to changes in foreign currency exchange rates, which include foreign currency forward contracts and cross-currency debt swaps. In addition, we use interest rate swaps to manage our exposure to changes in interest rates. All of our derivative assets and liabilities are recorded at fair value. See Notes 12 and 13 for more information on our derivatives.

Financial Instruments and Risk

Financial Instruments and Risk Management	9 Months Ended
	Nov. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments and Risk Management	Note 12 - Financial Instruments and Risk Management Foreign Currency Risk The U.S. Dollar is the functional currency for the Company and all of its subsidiaries and is also the reporting currency for the Company. By operating internationally, we are subject to foreign currency risk from transactions denominated in currencies other than the U.S. Dollar (“foreign currencies”). Such transactions include sales and operating expenses. As a result of such transactions, portions of our cash, trade accounts receivable and trade accounts payable are denominated in foreign currencies. Approximately 14% of our net sales revenue was denominated in foreign currencies during both the three and nine month periods ended November 30, 2023, respectively, compared to 15% and 13% for the same periods last year, respectively. These sales were primarily denominated in Euros, British Pounds and Canadian Dollars. We make most of our inventory purchases from manufacturers in Asia and primarily use the U.S. Dollar for such purchases. During the three and nine month periods ended November 30, 2023, we recorded foreign currency exchange rate net gains of $0.1 million and net losses of $0.3 million, respectively, in SG&A, compared to net gains of $1.1 million and net losses of $1.4 million for the same periods last year, respectively. We mitigate certain foreign currency exchange rate risk by using forward contracts and cross-currency debt swaps to protect against the foreign currency exchange rate risk inherent in our transactions denominated in foreign currencies. We do not enter into any derivatives or similar instruments for trading or other speculative purposes. Certain of our forward contracts are designated as cash flow hedges (“foreign currency contracts”) and are recorded on the balance sheet at fair value with changes in fair value recorded in Other Comprehensive Income (Loss) (“OCI”) until the hedge transaction is settled, at which point amounts are reclassified from Accumulated Other Comprehensive Income (Loss) (“AOCI”) to our condensed consolidated statements of income. Foreign currency derivatives for which we have not elected hedge accounting consist of certain forward contracts and cross-currency debt swaps, and any changes in the fair value of these derivatives are recorded in our condensed consolidated statements of income. These undesignated derivatives are used to hedge monetary net asset and liability positions. Cash flows from our foreign currency derivatives are classified as cash flows from operating activities in our condensed consolidated statements of cash flows, which is consistent with the classification of the cash flows from the underlying hedged item. We evaluate our derivatives designated as cash flow hedges each quarter to assess hedge effectiveness. Interest Rate Risk Interest on our outstanding debt as of November 30, 2023 is based on floating interest rates. If short-term interest rates increase, we will incur higher interest expense on any future outstanding balances of floating rate debt. Floating interest rates are hedged with interest rate swaps to effectively fix interest rates on a portion of our outstanding principal balance under the Credit Agreement, which totaled $737.2 million and $936.9 million as of November 30, 2023 and February 28, 2023, respectively. As of November 30, 2023 and February 28, 2023, $625.0 million and $425.0 million of the outstanding principal balance under the Credit Agreement, respectively, was hedged with interest rate swaps to fix the interest rate we pay. Our interest rate swaps are designated as cash flow hedges and are recorded on the balance sheet at fair value with changes in fair value recorded in OCI until the hedge transaction is settled, at which point amounts are reclassified from AOCI to our condensed consolidated statements of income. Cash flows from our interest rate swaps are classified as cash flows from operating activities in our condensed consolidated statements of cash flows, which is consistent with the classification of the cash flows from the underlying hedged item. We evaluate our derivatives designated as cash flow hedges each quarter to assess hedge effectiveness. The following tables summarize the fair values of our derivative instruments as of the end of the periods presented: (in thousands) November 30, 2023 Derivatives designated as hedging instruments Hedge Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 1/2025 € 32,000 $ — $ 44 $ 104 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 22,250 103 18 — 4 Forward contracts - sell Pounds Cash flow 2/2025 £ 26,760 — — 474 53 Forward contracts - sell Norwegian Kroner Cash flow 2/2024 kr 5,000 39 — — — Interest rate swaps Cash flow 2/2026 $ 625,000 2,006 1,111 — — Subtotal 2,148 1,173 578 57 Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 12/2023 € 740 — — 14 — Forward contracts - sell Pounds (1) 12/2023 £ 1,400 — — 50 — Subtotal — — 64 — Total fair value $ 2,148 $ 1,173 $ 642 $ 57 (in thousands) February 28, 2023 Derivatives designated as hedging instruments Hedge Type Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2024 € 29,310 $ 257 $ — $ — $ — Forward contracts - sell Canadian Dollars Cash flow 2/2024 $ 30,000 962 11 — — Forward contracts - sell Pounds Cash flow 1/2024 £ 19,400 — — 711 — Forward contracts - sell Norwegian Kroner Cash flow 2/2024 kr 40,000 185 — — — Interest rate swaps Cash flow 2/2026 $ 425,000 3,941 1,805 — — Subtotal 5,345 1,816 711 — Derivatives not designated under hedge accounting Forward contracts - buy Euro (1) 3/2023 € 500 6 — — — Forward contracts - buy Pounds (1) 3/2023 £ 400 2 — — — Subtotal 8 — — — Total fair value $ 5,353 $ 1,816 $ 711 $ — (1) These forward contracts, for which we have not elected hedge accounting, hedge monetary net asset and liability positions for the notional amounts reported, creating an economic hedge against currency movements. The pre-tax effects of derivative instruments designated as cash flow hedges were as follows for the periods presented: Three Months Ended November 30, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2023 2022 Location 2023 2022 Foreign currency contracts - cash flow hedges $ 278 $ (685) Sales revenue, net $ 212 $ 4,484 Interest rate swaps - cash flow hedges 8 1,471 Interest expense 2,213 168 Total $ 286 $ 786 $ 2,425 $ 4,652 Nine Months Ended November 30, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2023 2022 Location 2023 2022 Foreign currency contracts - cash flow hedges $ (968) $ 7,860 Sales revenue, net $ 167 $ 8,395 Interest rate swaps - cash flow hedges 3,018 5,100 Interest expense 5,647 (793) Total $ 2,050 $ 12,960 $ 5,814 $ 7,602 The pre-tax effects of derivative instruments not designated under hedge accounting were as follows for the periods presented: Gain (Loss) Three Months Ended November 30, Nine Months Ended November 30, (in thousands) Location 2023 2022 2023 2022 Forward contracts SG&A $ (225) $ (12) $ (265) $ (262) Cross-currency debt swaps - principal SG&A — — — 875 Total $ (225) $ (12) $ (265) $ 613 We expect a net gain of $1.6 million associated with foreign currency contracts and interest rate swaps currently recorded in AOCI to be reclassified into income over the next twelve months. The amount ultimately realized, however, will differ as exchange rates and interest rates change and the underlying contracts settle. See Notes 11 and 13 to these condensed consolidated financial statements for more information. Counterparty Credit Risk Financial instruments, including foreign currency contracts, forward contracts, cross-currency debt swaps and interest rate swaps, expose us to counterparty credit risk for non-performance. We manage our exposure to counterparty credit risk by only dealing with counterparties who are substantial international financial institutions with significant experience using such derivative instruments. We believe that the risk of incurring credit losses is remote.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Nov. 30, 2023
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Accumulated Other Comprehensive Income (Loss)	Note 13 - Accumulated Other Comprehensive Income (Loss) The changes in AOCI by component and related tax effects for the periods presented were as follows: (in thousands) Interest Foreign Total Balance at February 28, 2022 $ (2,126) $ 2,328 $ 202 Other comprehensive income before reclassification 5,100 7,860 12,960 Amounts reclassified out of AOCI 793 (8,395) (7,602) Tax effects (1,391) (30) (1,421) Other comprehensive income (loss) 4,502 (565) 3,937 Balance at November 30, 2022 $ 2,376 $ 1,763 $ 4,139 Balance at February 28, 2023 $ 4,394 $ 553 $ 4,947 Other comprehensive income (loss) before reclassification 3,018 (968) 2,050 Amounts reclassified out of AOCI (5,647) (167) (5,814) Tax effects 619 256 875 Other comprehensive loss (2,010) (879) (2,889) Balance at November 30, 2023 $ 2,384 $ (326) $ 2,058 See Notes 10, 11 and 12 to these condensed consolidated financial statements for additional information regarding our cash flow hedges.

Segment Information

Segment Information	9 Months Ended
	Nov. 30, 2023
Segment Reporting [Abstract]
Segment Information	Note 14 - Segment Information We currently operate two reportable segments consisting of Home & Outdoor and Beauty & Wellness. During the fourth quarter of fiscal 2023, we made changes to the structure of our organization in connection with our global restructuring plan that resulted in our previous Health & Wellness and Beauty operating segments being combined into a single reportable segment, which is referred to herein as “Beauty & Wellness.” Comparative prior period segment information in this report has been recast to conform to this change in our reportable segments. See Note 1 to these condensed consolidated financial statements for additional information. The following tables summarize segment information for the periods presented: Three Months Ended November 30, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 235,948 $ 313,666 $ 549,614 Restructuring charges 583 3,307 3,890 Operating income 49,514 57,413 106,927 Capital and intangible asset expenditures 7,674 1,450 9,124 Depreciation and amortization 6,025 6,406 12,431 Three Months Ended November 30, 2022 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 228,937 $ 329,669 $ 558,606 Restructuring charges 5,090 5,373 10,463 Operating income 30,847 46,346 77,193 Capital and intangible asset expenditures 28,788 4,771 33,559 Depreciation and amortization 4,716 6,997 11,713 Nine Months Ended November 30, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 693,069 $ 822,780 $ 1,515,849 Restructuring charges 4,644 10,218 14,862 Operating income 107,729 86,684 194,413 Capital and intangible asset expenditures 23,513 6,168 29,681 Depreciation and amortization 17,033 20,004 37,037 Nine Months Ended November 30, 2022 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 703,759 $ 884,325 $ 1,588,084 Restructuring charges 5,562 9,679 15,241 Operating income 102,722 55,356 158,078 Capital and intangible asset expenditures 133,939 12,255 146,194 Depreciation and amortization 13,704 19,626 33,330 The following table presents net sales revenue by geographic region, in U.S. Dollars: Three Months Ended November 30, Nine Months Ended November 30, (in thousands) 2023 2022 2023 2022 Domestic sales revenue, net (1) $ 428,582 78.0 % $ 437,894 78.4 % $ 1,176,190 77.6 % $ 1,254,545 79.0 % International sales revenue, net 121,032 22.0 % 120,712 21.6 % 339,659 22.4 % 333,539 21.0 % Total sales revenue, net $ 549,614 100.0 % $ 558,606 100.0 % $ 1,515,849 100.0 % $ 1,588,084 100.0 % (1) Beginning in the fourth quarter of fiscal 2023, we included net sales revenue from the U.S. and Canada as domestic net sales revenue. Previously, we reported sales revenue from Canada within international net sales revenue. We have recast the prior period domestic and international net sales revenue presented to conform with this current presentation.

Income Taxes

Income Taxes	9 Months Ended
	Nov. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 - Income Taxes We reorganized the Company in Bermuda in 1994 and many of our foreign subsidiaries are not directly or indirectly owned by a U.S. parent. As such, a large portion of our foreign income is not subject to U.S. taxation on a permanent basis under current law. Additionally, our intellectual property is largely owned by foreign subsidiaries, resulting in proportionally higher earnings in jurisdictions with lower statutory tax rates, which decreases our overall effective tax rate. The taxable income earned in each jurisdiction, whether U.S. or foreign, is determined by the subsidiary's operating results and transfer pricing and tax regulations in the related jurisdictions. For interim periods, our income tax expense and resulting effective tax rate are based upon an estimated annual effective tax rate adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. For the three months ended November 30, 2023, income tax expense as a percentage of income before income tax was 19.5% compared to 19.1% for the same period last year. The year-over-year increase in the effective tax rate is primarily due to tax expense recognized for the gain on the sale of our distribution and office facilities in El Paso, Texas during the third quarter of fiscal 2023 and an increase in tax expense for other discrete items, partially offset by shifts in the mix of income in our various tax jurisdictions. For the nine months ended November 30, 2023, income tax expense as a percentage of income before income tax was 18.4% compared to 18.6% for the same period last year primarily due to a decrease in tax expense for discrete items (excluding the gain on the sale of our El Paso facilities) and shifts in the mix of income in our various tax jurisdictions, partially offset by tax expense recognized for

Earnings Per Share

Earnings Per Share	9 Months Ended
	Nov. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Note 16 - Earnings Per Share We compute basic earnings per share using the weighted average number of shares of common stock outstanding during the period. We compute diluted earnings per share using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities. Dilutive securities at any given point in time may consist of outstanding options to purchase common stock and issued and contingently issuable unvested restricted stock units, performance stock units, restricted stock awards and performance restricted stock awards and other stock-based awards. Anti-dilutive securities are not included in the computation of diluted earnings per share under the treasury stock method. See Note 6 to these condensed consolidated financial statements for more information regarding stock-based awards. The following table presents our weighted average basic and diluted shares outstanding for the periods shown: Three Months Ended November 30, Nine Months Ended November 30, (in thousands) 2023 2022 2023 2022 Weighted average shares outstanding, basic 23,743 23,991 23,903 23,942 Incremental shares from share-based compensation arrangements 70 87 93 144 Weighted average shares outstanding, diluted 23,813 24,078 23,996 24,086 Anti-dilutive securities 9 53 57 45

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022
Pay vs Performance Disclosure
Net income	$ 75,898	$ 51,826	$ 125,860	$ 107,093

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Nov. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation and Rel_2

Basis of Presentation and Related Information (Policies)	9 Months Ended
	Nov. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include all of our subsidiaries. Our condensed consolidated financial statements are prepared in U.S. Dollars. All intercompany balances and transactions are eliminated in consolidation. The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results may differ materially from those estimates.
Reclassifications	Reclassifications We have reclassified or combined certain amounts in the prior year's accompanying footnotes to conform with the current year's presentation.
New Accounting Pronouncements	Adopted In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations , which requires a buyer in a supplier finance program to disclose qualitative and quantitative information about its program to allow a user of the financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. The amendments in ASU 2022-04 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with the exception for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The guidance should be applied retrospectively, except for the amendment on rollforward information, which should be applied prospectively. This ASU was effective for us in the first quarter of fiscal 2024, with the exception of the amendment on rollforward information, which will be effective for us in our Form 10-K for fiscal 2025. We adopted this ASU during the first quarter of fiscal 2024 and the adoption did not have an impact on our consolidated financial statement disclosures. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers . Prior to the issuance of this guidance, contract assets and contract liabilities were recognized by the acquirer at fair value on the acquisition date. The amendments in ASU 2021-08 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, and should be applied prospectively to acquisitions occurring on or after the effective date. We adopted this ASU during the first quarter of fiscal 2024 and the adoption did not have an impact on our consolidated financial statements. Not Yet Adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. This ASU will be effective for our Form 10-K for fiscal 2025 and our Form 10-Q for the first quarter of fiscal 2026. We are currently evaluating the impact this ASU may have on our consolidated financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied prospectively; however, retrospective application is also permitted. This ASU will be effective for our Form 10-K for fiscal 2026. We are currently evaluating the impact this ASU may have on our consolidated financial statement disclosures.

Acquisition of Curlsmith (Table

Acquisition of Curlsmith (Tables)	9 Months Ended
	Nov. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of business acquisitions, by acquisition	The following table presents the estimated fair values of assets acquired and liabilities assumed at the acquisition date: (in thousands) Assets: Receivables $ 4,211 Inventory 7,890 Prepaid expenses and other current assets 119 Property and equipment 212 Goodwill 117,108 Trade names - definite 21,000 Customer relationships - definite 12,000 Deferred tax assets, net 360 Total assets 162,900 Liabilities: Accounts payable 1,401 Accrued expenses and other current liabilities 2,813 Income taxes payable 2,572 Deferred tax liabilities, net 8,187 Total liabilities 14,973 Net assets recorded $ 147,927
Business acquisition, pro forma information	The impact of the acquisition of Curlsmith on our condensed consolidated statements of income for the periods presented was as follows: (in thousands, except earnings per share data) Three Months Ended November 30, 2022 (1) Nine Months Ended November 30, 2022 (1) (2) Sales revenue, net $ 13,091 $ 26,544 Net income 2,077 3,953 EPS: Basic $ 0.09 $ 0.17 Diluted $ 0.09 $ 0.16 (1) Net income and EPS amounts include allocations for corporate expenses, interest expense and income tax expense. (2) Represents approximately thirty-two weeks of operating results from Curlsmith, acquired April 22, 2022. The following supplemental unaudited pro forma information presents our financial results as if the acquisition of Curlsmith had occurred on March 1, 2021. This supplemental pro forma information has been prepared for comparative purposes and does not necessarily indicate what may have occurred if the acquisition had been completed on March 1, 2021, and this information is not intended to be indicative of future results. (in thousands, except earnings per share data) Three Months Ended November 30, 2022 Nine Months Ended Sales revenue, net $ 558,606 $ 1,595,176 Net income 51,826 109,006 EPS: Basic $ 2.16 $ 4.55 Diluted $ 2.15 $ 4.53

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Nov. 30, 2023
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	A summary of accrued expenses and other current liabilities was as follows: (in thousands) November 30, 2023 February 28, 2023 Accrued compensation, benefits and payroll taxes $ 37,905 $ 17,380 Accrued sales discounts and allowances 60,267 63,881 Accrued sales returns 25,584 28,498 Accrued advertising 43,224 36,931 Other 64,536 54,028 Total accrued expenses and other current liabilities $ 231,516 $ 200,718

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	9 Months Ended
	Nov. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-based compensation expense in SG&A	We recorded share-based compensation expense in SG&A as follows: Three Months Ended November 30, Nine Months Ended (in thousands) 2023 2022 2023 2022 Directors stock compensation $ 197 $ 197 $ 590 $ 592 Service Condition Awards 3,160 2,211 9,358 7,488 Performance Condition Awards 1,170 3,252 4,306 17,293 Market Condition Awards 3,458 1,793 9,647 5,620 Employee stock purchase plan 594 488 1,204 1,062 Share-based compensation expense 8,579 7,941 25,105 32,055 Less income tax benefits (532) (474) (1,558) (2,128) Share-based compensation expense, net of income tax benefits $ 8,047 $ 7,467 $ 23,547 $ 29,927

Repurchases of Common Stock (Ta

Repurchases of Common Stock (Tables)	9 Months Ended
	Nov. 30, 2023
Equity [Abstract]
Summary of share repurchase activity	The following table summarizes our share repurchase activity for the periods shown: Three Months Ended November 30, Nine Months Ended November 30, (in thousands, except share and per share data) 2023 2022 2023 2022 Common stock repurchased on the open market: Number of shares — — 381,200 — Aggregate value of shares $ — $ — $ 50,006 $ — Average price per share $ — $ — $ 131.18 $ — Common stock received in connection with share-based compensation: Number of shares 2,701 382 48,098 90,341 Aggregate value of shares $ 306 $ 45 $ 4,835 $ 18,350 Average price per share $ 113.31 $ 117.44 $ 100.51 $ 203.12

Restructuring Plan (Tables)

Restructuring Plan (Tables)	9 Months Ended
	Nov. 30, 2023
Restructuring and Related Activities [Abstract]
Summary of restructuring charges recorded	The following tables summarize restructuring charges recorded as a result of Project Pegasus for the periods presented: Three Months Ended November 30, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 109 $ 2,498 $ 2,607 Professional fees 464 794 1,258 Contract termination — — — Other 10 15 25 Total restructuring charges $ 583 $ 3,307 $ 3,890 Three Months Ended November 30, 2022 (in thousands) Home & Beauty & Total Severance and employee related costs $ 426 $ 749 $ 1,175 Professional fees 4,663 4,511 9,174 Contract termination — — — Other 1 113 114 Total restructuring charges $ 5,090 $ 5,373 $ 10,463 Nine Months Ended November 30, 2023 Total (in thousands) Home & Beauty & Wellness Total Severance and employee related costs $ 680 $ 3,407 $ 4,087 $ 13,540 Professional fees 3,915 5,870 9,785 26,534 Contract termination — 796 796 1,331 Other 49 145 194 819 Total restructuring charges $ 4,644 $ 10,218 $ 14,862 $ 42,224 Nine Months Ended November 30, 2022 (in thousands) Home & Beauty & Total Severance and employee related costs $ 898 $ 3,120 $ 4,018 Professional fees 4,663 4,639 9,302 Contract termination — 1,500 1,500 Other 1 420 421 Total restructuring charges $ 5,562 $ 9,679 $ 15,241
Rollforward of restructuring reserve	The tables below present a rollforward of our accruals related to Project Pegasus, which are included in accounts payable and accrued expenses and other current liabilities: (in thousands) Balance at February 28, 2023 Charges Payments Balance at November 30, 2023 Severance and employee related costs $ 3,173 $ 4,087 $ (3,758) $ 3,502 Professional fees 3,201 9,785 (12,559) 427 Contract termination 160 796 (956) — Other 34 194 (228) — Total $ 6,568 $ 14,862 $ (17,501) $ 3,929 (in thousands) Balance at February 28, 2022 Charges Payments Balance at November 30, 2022 Severance and employee related costs $ — $ 4,018 $ (2,805) $ 1,213 Professional fees — 9,302 (2,196) 7,106 Contract termination — 1,500 — 1,500 Other — 421 (414) 7 Total $ — $ 15,241 $ (5,415) $ 9,826

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Nov. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of production related impairments	The following table provides a summary of EPA compliance costs incurred during the periods presented: Three Months Ended November 30, Nine Months Ended November 30, (in thousands) 2023 2022 2023 2022 Cost of goods sold $ — $ 370 $ — $ 16,928 1 SG&A — 1,733 — 5,173 Total EPA compliance costs $ — $ 2,103 $ — $ 22,101 (1)

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Nov. 30, 2023
Debt Disclosure [Abstract]
Summary of long-term debt	A summary of our long-term debt follows: (in thousands) November 30, 2023 February 28, 2023 Credit Agreement (1): Revolving loans $ 495,000 $ 690,000 Term loans 242,188 246,875 Total borrowings under Credit Agreement 737,188 936,875 Unamortized prepaid financing fees (1,540) (2,463) Total long-term debt 735,648 934,412 Less: current maturities of long-term debt (6,235) (6,064) Long-term debt, excluding current maturities $ 729,413 $ 928,348 (1) The weighted average interest rates on borrowings outstanding under the Credit Agreement (defined below) as of November 30, 2023 and February 28, 2023 were 7.1% and 6.6%, respectively.

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Nov. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of carrying value and fair value of financial assets and liabilities recorded at fair value and measured on a recurring basis and classified as level 2	The following table presents the fair value of our financial assets and liabilities: Fair Value (in thousands) November 30, 2023 February 28, 2023 Assets: Cash equivalents (money market accounts) $ 2,829 $ 381 U.S. Treasury Bills 7,435 — Interest rate swaps 3,117 5,746 Foreign currency derivatives 204 1,423 Total assets $ 13,585 $ 7,550 Liabilities: Foreign currency derivatives 699 711 Total liabilities $ 699 $ 711

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	9 Months Ended
	Nov. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair values of derivative instruments	The following tables summarize the fair values of our derivative instruments as of the end of the periods presented: (in thousands) November 30, 2023 Derivatives designated as hedging instruments Hedge Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 1/2025 € 32,000 $ — $ 44 $ 104 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 22,250 103 18 — 4 Forward contracts - sell Pounds Cash flow 2/2025 £ 26,760 — — 474 53 Forward contracts - sell Norwegian Kroner Cash flow 2/2024 kr 5,000 39 — — — Interest rate swaps Cash flow 2/2026 $ 625,000 2,006 1,111 — — Subtotal 2,148 1,173 578 57 Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 12/2023 € 740 — — 14 — Forward contracts - sell Pounds (1) 12/2023 £ 1,400 — — 50 — Subtotal — — 64 — Total fair value $ 2,148 $ 1,173 $ 642 $ 57 (in thousands) February 28, 2023 Derivatives designated as hedging instruments Hedge Type Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2024 € 29,310 $ 257 $ — $ — $ — Forward contracts - sell Canadian Dollars Cash flow 2/2024 $ 30,000 962 11 — — Forward contracts - sell Pounds Cash flow 1/2024 £ 19,400 — — 711 — Forward contracts - sell Norwegian Kroner Cash flow 2/2024 kr 40,000 185 — — — Interest rate swaps Cash flow 2/2026 $ 425,000 3,941 1,805 — — Subtotal 5,345 1,816 711 — Derivatives not designated under hedge accounting Forward contracts - buy Euro (1) 3/2023 € 500 6 — — — Forward contracts - buy Pounds (1) 3/2023 £ 400 2 — — — Subtotal 8 — — — Total fair value $ 5,353 $ 1,816 $ 711 $ — (1)
Schedule of pre-tax effect of derivative instruments designated as hedges	The pre-tax effects of derivative instruments designated as cash flow hedges were as follows for the periods presented: Three Months Ended November 30, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2023 2022 Location 2023 2022 Foreign currency contracts - cash flow hedges $ 278 $ (685) Sales revenue, net $ 212 $ 4,484 Interest rate swaps - cash flow hedges 8 1,471 Interest expense 2,213 168 Total $ 286 $ 786 $ 2,425 $ 4,652 Nine Months Ended November 30, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2023 2022 Location 2023 2022 Foreign currency contracts - cash flow hedges $ (968) $ 7,860 Sales revenue, net $ 167 $ 8,395 Interest rate swaps - cash flow hedges 3,018 5,100 Interest expense 5,647 (793) Total $ 2,050 $ 12,960 $ 5,814 $ 7,602
Schedule of pre-tax effect of derivative instruments not designated as hedges	The pre-tax effects of derivative instruments not designated under hedge accounting were as follows for the periods presented: Gain (Loss) Three Months Ended November 30, Nine Months Ended November 30, (in thousands) Location 2023 2022 2023 2022 Forward contracts SG&A $ (225) $ (12) $ (265) $ (262) Cross-currency debt swaps - principal SG&A — — — 875 Total $ (225) $ (12) $ (265) $ 613

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Nov. 30, 2023
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Summary of changes in accumulated other comprehensive income (loss)	The changes in AOCI by component and related tax effects for the periods presented were as follows: (in thousands) Interest Foreign Total Balance at February 28, 2022 $ (2,126) $ 2,328 $ 202 Other comprehensive income before reclassification 5,100 7,860 12,960 Amounts reclassified out of AOCI 793 (8,395) (7,602) Tax effects (1,391) (30) (1,421) Other comprehensive income (loss) 4,502 (565) 3,937 Balance at November 30, 2022 $ 2,376 $ 1,763 $ 4,139 Balance at February 28, 2023 $ 4,394 $ 553 $ 4,947 Other comprehensive income (loss) before reclassification 3,018 (968) 2,050 Amounts reclassified out of AOCI (5,647) (167) (5,814) Tax effects 619 256 875 Other comprehensive loss (2,010) (879) (2,889) Balance at November 30, 2023 $ 2,384 $ (326) $ 2,058

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Nov. 30, 2023
Segment Reporting [Abstract]
Schedule of segment information	The following tables summarize segment information for the periods presented: Three Months Ended November 30, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 235,948 $ 313,666 $ 549,614 Restructuring charges 583 3,307 3,890 Operating income 49,514 57,413 106,927 Capital and intangible asset expenditures 7,674 1,450 9,124 Depreciation and amortization 6,025 6,406 12,431 Three Months Ended November 30, 2022 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 228,937 $ 329,669 $ 558,606 Restructuring charges 5,090 5,373 10,463 Operating income 30,847 46,346 77,193 Capital and intangible asset expenditures 28,788 4,771 33,559 Depreciation and amortization 4,716 6,997 11,713 Nine Months Ended November 30, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 693,069 $ 822,780 $ 1,515,849 Restructuring charges 4,644 10,218 14,862 Operating income 107,729 86,684 194,413 Capital and intangible asset expenditures 23,513 6,168 29,681 Depreciation and amortization 17,033 20,004 37,037 Nine Months Ended November 30, 2022 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 703,759 $ 884,325 $ 1,588,084 Restructuring charges 5,562 9,679 15,241 Operating income 102,722 55,356 158,078 Capital and intangible asset expenditures 133,939 12,255 146,194 Depreciation and amortization 13,704 19,626 33,330 The following table presents net sales revenue by geographic region, in U.S. Dollars: Three Months Ended November 30, Nine Months Ended November 30, (in thousands) 2023 2022 2023 2022 Domestic sales revenue, net (1) $ 428,582 78.0 % $ 437,894 78.4 % $ 1,176,190 77.6 % $ 1,254,545 79.0 % International sales revenue, net 121,032 22.0 % 120,712 21.6 % 339,659 22.4 % 333,539 21.0 % Total sales revenue, net $ 549,614 100.0 % $ 558,606 100.0 % $ 1,515,849 100.0 % $ 1,588,084 100.0 % (1) Beginning in the fourth quarter of fiscal 2023, we included net sales revenue from the U.S. and Canada as domestic net sales revenue. Previously, we reported sales revenue from Canada within international net sales revenue. We have recast the prior period domestic and international net sales revenue presented to conform with this current presentation.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Nov. 30, 2023
Earnings Per Share [Abstract]
Schedule of components of basic and diluted shares	The following table presents our weighted average basic and diluted shares outstanding for the periods shown: Three Months Ended November 30, Nine Months Ended November 30, (in thousands) 2023 2022 2023 2022 Weighted average shares outstanding, basic 23,743 23,991 23,903 23,942 Incremental shares from share-based compensation arrangements 70 87 93 144 Weighted average shares outstanding, diluted 23,813 24,078 23,996 24,086 Anti-dilutive securities 9 53 57 45

Basis of Presentation and Rel_3

Basis of Presentation and Related Information (Details) $ / shares in Units, $ in Thousands				3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 22, 2022 USD ($)	Mar. 25, 2022 USD ($)	Jun. 07, 2021 USD ($)	Nov. 30, 2023 segment $ / shares	May 31, 2023 USD ($)	Nov. 30, 2023 USD ($) segment $ / shares	Nov. 30, 2022 USD ($)	Feb. 28, 2023 USD ($) $ / shares	Sep. 28, 2023 USD ($)
Discontinued Operations
Common shares, par value (in dollars per share) | $ / shares				$ 0.10		$ 0.10		$ 0.10
Number of segments | segment				2		2
Net payments to acquire businesses, net of cash acquired						$ 0	$ 146,342
Proceeds from sale of personal care business			$ 44,700			0	1,804
Gain on sale of North America Personal Care business			$ 500			$ 0	$ 1,336
Distribution and Office Facilities, El Paso, Texas
Discontinued Operations
Purchase price from sale									$ 50,600
Latin America and Caribbean Personal Care Business
Discontinued Operations
Proceeds from sale of personal care business		$ 1,800
Gain on sale of North America Personal Care business		$ 1,300
Curlsmith
Discontinued Operations
Net payments to acquire businesses, net of cash acquired	$ 147,900
Adjustments to goodwill					$ 300			$ 100

Gain on Sale of Distribution _2

Gain on Sale of Distribution and Office Facilities (Details) - Distribution and Office Facilities, El Paso, Texas - USD ($) $ in Millions		3 Months Ended
	Sep. 28, 2023	Nov. 30, 2023
Sale Leaseback Transaction [Line Items]
Purchase price from sale	$ 50.6
Transaction costs	$ 1.1
Term of lease	18 months
Fair value of prepaid rent	$ 1.9
Increase in purchase price		$ 1.9
Accumulated depreciation on asset held-for-sale	36.8
Disposal Group, Held-for-Sale, Not Discontinued Operations
Sale Leaseback Transaction [Line Items]
Expected gain on sale		34.2
Property and equipment transferred to assets held-for-sale	$ 17.2
Disposal Group, Held-for-Sale, Not Discontinued Operations | Beauty & Wellness
Sale Leaseback Transaction [Line Items]
Expected gain on sale		18
Disposal Group, Held-for-Sale, Not Discontinued Operations | Home & Outdoor
Sale Leaseback Transaction [Line Items]
Expected gain on sale		$ 16.2

Acquisition of Curlsmith - Narr

Acquisition of Curlsmith - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended		12 Months Ended
	Apr. 22, 2022	May 31, 2023	Nov. 30, 2023	Nov. 30, 2022	Feb. 28, 2023
Business Acquisition [Line Items]
Net payments to acquire businesses			$ 0	$ 146,342
Curlsmith
Business Acquisition [Line Items]
Net payments to acquire businesses	$ 147,900
Net working capital adjustment	2,100
Acquisition related expenses				$ 2,700
Adjustments to goodwill		$ 300			$ 100
Net working capital adjustment, goodwill					1,800
Reduction to total purchase consideration					$ 1,800
Receivables	4,211
Curlsmith | Trade Names
Business Acquisition [Line Items]
Up-front license fee	$ 21,000
Expected life	20 years
Curlsmith | Customer Relationships
Business Acquisition [Line Items]
Up-front license fee	$ 12,000
Expected life	19 years 6 months

Acquisition of Curlsmith - Busi

Acquisition of Curlsmith - Business Acquisitions, by Acquisition (Details) - USD ($) $ in Thousands	Nov. 30, 2023	Feb. 28, 2023	Apr. 22, 2022
Assets
Goodwill	$ 1,066,730	$ 1,066,479
Curlsmith
Assets
Receivables			$ 4,211
Inventory			7,890
Prepaid expenses and other current assets			119
Property and equipment			212
Goodwill			117,108
Deferred tax assets, net			360
Total assets			162,900
Liabilities:
Accounts payable			1,401
Accrued expenses and other current liabilities			2,813
Income taxes payable			2,572
Deferred tax liabilities, net			8,187
Total liabilities			14,973
Net assets recorded			147,927
Curlsmith | Trade Names
Assets
Trade names and customer relationships - definite			21,000
Curlsmith | Customer Relationships
Assets
Trade names and customer relationships - definite			$ 12,000

Acquisition of Curlsmith - Impa

Acquisition of Curlsmith - Impact of the Acquisition of Curlsmith on Income (Details) - Curlsmith - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Nov. 30, 2022	Nov. 30, 2022
Business Acquisition [Line Items]
Sales revenue, net	$ 13,091	$ 26,544
Net income	$ 2,077	$ 3,953
EPS:
Basic (in dollars per share)	$ 0.09	$ 0.17
Diluted (in dollars per share)	$ 0.09	$ 0.16

Acquisition of Curlsmith - Pro

Acquisition of Curlsmith - Pro Forma Information (Details) - Curlsmith - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Nov. 30, 2022	Nov. 30, 2022
Business Acquisition [Line Items]
Sales revenue, net	$ 558,606	$ 1,595,176
Net income	$ 51,826	$ 109,006
EPS:
Basic (in dollars per share)	$ 2.16	$ 4.55
Diluted (in dollars per share)	$ 2.15	$ 4.53

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Nov. 30, 2023	Feb. 28, 2023
Payables and Accruals [Abstract]
Accrued compensation, benefits and payroll taxes	$ 37,905	$ 17,380
Accrued sales discounts and allowances	60,267	63,881
Accrued sales returns	25,584	28,498
Accrued advertising	43,224	36,931
Other	64,536	54,028
Accrued expenses and other current liabilities	$ 231,516	$ 200,718

Share-Based Compensation Plan_2

Share-Based Compensation Plans - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended
	May 31, 2023	Nov. 30, 2023
Share-based compensation plans
Expected recognition period for unrecognized share-based compensation		1 year 10 months 24 days
Target achievement for performance condition awards, as a percentage		0%
Restricted Stock
Share-based compensation plans
Number of awards granted (in shares)	252,522
Unrecognized share-based compensation		$ 25.8
Service Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	94,807
Grant date fair value of shares granted in period (in dollars per share)	$ 110.85
Market Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	126,204
Grant date fair value of shares granted in period (in dollars per share)	$ 80.50
Performance Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	126,318
Grant date fair value of shares granted in period (in dollars per share)	$ 110.85

Share-Based Compensation Plan_3

Share-Based Compensation Plans - Share-Based Compensation Expense in SG&A (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense, net of income tax benefits	$ 8,047	$ 7,467	$ 23,547	$ 29,927
SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	8,579	7,941	25,105	32,055
Less income tax benefits	(532)	(474)	(1,558)	(2,128)
Service Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	3,160	2,211	9,358	7,488
Performance Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,170	3,252	4,306	17,293
Market Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	3,458	1,793	9,647	5,620
Employee stock purchase plan | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	594	488	1,204	1,062
Directors stock compensation | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 197	$ 197	$ 590	$ 592

Repurchases of Common Stock - N

Repurchases of Common Stock - Narrative (Details) - USD ($)	Aug. 25, 2021	Nov. 30, 2023	Aug. 31, 2021
Equity [Abstract]
Amount of shares authorized for purchase			$ 500,000,000
Period for stock repurchase	3 years
Remaining share repurchase amount		$ 348,800,000

Repurchases of Common Stock - S

Repurchases of Common Stock - Summary of Share Repurchase Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Nov. 30, 2023	Aug. 31, 2023	May 31, 2023	Nov. 30, 2022	Aug. 31, 2022	May 31, 2022	Nov. 30, 2023	Nov. 30, 2022
Repurchase of common stock
Aggregate value of shares	$ 306	$ 50,089	$ 4,446	$ 45	$ 81	$ 18,224
Stock Compensation Plan
Repurchase of common stock
Number of shares (in shares)	2,701			382			48,098	90,341
Aggregate value of shares	$ 306			$ 45			$ 4,835	$ 18,350
Average price per share (in dollars per share)	$ 113.31			$ 117.44			$ 100.51	$ 203.12
Open Market
Repurchase of common stock
Number of shares (in shares)	0			0			381,200	0
Aggregate value of shares	$ 0			$ 0			$ 50,006	$ 0
Average price per share (in dollars per share)	$ 0			$ 0			$ 131.18	$ 0

Restructuring Plan - Narrative

Restructuring Plan - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		18 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Aug. 31, 2023	Feb. 28, 2023
Restructuring Plan
Restructuring charges	$ 3,890	$ 10,463	$ 14,862	$ 15,241
Beauty & Wellness
Restructuring Plan
Restructuring charges	$ 3,307	5,373	10,218	9,679
Project Pegasus
Restructuring Plan
Estimated percentage of workforce reduction							10%
Estimated percentage reduction in cost of goods sold	60%
Estimated percentage reduction in SG&A expenses	40%
Restructuring charges	$ 3,890	10,463	14,862	15,241	$ 42,224
Project Pegasus | Home & Outdoor
Restructuring Plan
Restructuring charges	583	5,090	4,644	5,562
Project Pegasus | Beauty & Wellness
Restructuring Plan
Restructuring charges	3,307	$ 5,373	10,218	9,679
Project Pegasus | Severance and employee related costs
Restructuring Plan
Restructuring charges			4,087	4,018
Project Pegasus | Professional fees
Restructuring Plan
Expected restructuring costs						$ 30,000
Restructuring charges			9,785	9,302
Project Pegasus | Contract termination
Restructuring Plan
Expected restructuring costs						5,000
Restructuring charges			796	1,500
Project Pegasus | Other
Restructuring Plan
Restructuring charges			$ 194	$ 421
Project Pegasus | Fiscal 2024
Restructuring Plan
Estimated percentage of savings recognized			25%
Project Pegasus | Fiscal 2025
Restructuring Plan
Estimated percentage of savings recognized			50%
Project Pegasus | Fiscal 2026
Restructuring Plan
Estimated percentage of savings recognized			25%
Project Pegasus | Minimum
Restructuring Plan
Expected restructuring costs	60,000		$ 60,000		60,000
Annualized profit improvements	75,000
Project Pegasus | Minimum | Home & Outdoor
Restructuring Plan
Expected restructuring costs						17,000
Project Pegasus | Minimum | Beauty & Wellness
Restructuring Plan
Expected restructuring costs						43,000
Project Pegasus | Minimum | Severance and employee related costs
Restructuring Plan
Expected restructuring costs						22,000
Project Pegasus | Minimum | Other
Restructuring Plan
Expected restructuring costs						3,000
Project Pegasus | Maximum
Restructuring Plan
Expected restructuring costs	65,000		$ 65,000		$ 65,000
Annualized profit improvements	$ 85,000
Project Pegasus | Maximum | Home & Outdoor
Restructuring Plan
Expected restructuring costs						19,000
Project Pegasus | Maximum | Beauty & Wellness
Restructuring Plan
Expected restructuring costs						46,000
Project Pegasus | Maximum | Severance and employee related costs
Restructuring Plan
Expected restructuring costs						25,000
Project Pegasus | Maximum | Other
Restructuring Plan
Expected restructuring costs						$ 5,000

Restructuring Plan - Restructur

Restructuring Plan - Restructuring Charges to Date (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		18 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023
Restructuring Plan
Total restructuring charges	$ 3,890	$ 10,463	$ 14,862	$ 15,241
Project Pegasus
Restructuring Plan
Severance and employee related costs	2,607	1,175	4,087	4,018	$ 13,540
Professional fees	1,258	9,174	9,785	9,302	26,534
Contract termination	0	0	796	1,500	1,331
Other	25	114	194	421	819
Total restructuring charges	3,890	10,463	14,862	15,241	$ 42,224
Home & Outdoor | Project Pegasus
Restructuring Plan
Severance and employee related costs	109	426	680	898
Professional fees	464	4,663	3,915	4,663
Contract termination	0	0	0	0
Other	10	1	49	1
Total restructuring charges	583	5,090	4,644	5,562
Beauty & Wellness
Restructuring Plan
Total restructuring charges	3,307	5,373	10,218	9,679
Beauty & Wellness | Project Pegasus
Restructuring Plan
Severance and employee related costs	2,498	749	3,407	3,120
Professional fees	794	4,511	5,870	4,639
Contract termination	0	0	796	1,500
Other	15	113	145	420
Total restructuring charges	$ 3,307	$ 5,373	$ 10,218	$ 9,679

Restructuring Plan - Reserve Ro

Restructuring Plan - Reserve Roll Forward (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		18 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023
Restructuring Reserve [Roll Forward]
Charges	$ 3,890	$ 10,463	$ 14,862	$ 15,241
Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance			6,568	0
Charges	3,890	10,463	14,862	15,241	$ 42,224
Payments			(17,501)	(5,415)
Restructuring liability, ending balance	3,929	9,826	3,929	9,826	3,929
Severance and employee related costs | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance			3,173	0
Charges			4,087	4,018
Payments			(3,758)	(2,805)
Restructuring liability, ending balance	3,502	1,213	3,502	1,213	3,502
Professional fees | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance			3,201	0
Charges			9,785	9,302
Payments			(12,559)	(2,196)
Restructuring liability, ending balance	427	7,106	427	7,106	427
Contract termination | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance			160	0
Charges			796	1,500
Payments			(956)	0
Restructuring liability, ending balance	0	1,500	0	1,500	0
Other | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance			34	0
Charges			194	421
Payments			(228)	(414)
Restructuring liability, ending balance	$ 0	$ 7	$ 0	$ 7	$ 0

Commitments and Contingencies_2

Commitments and Contingencies (Details) $ in Thousands	1 Months Ended	3 Months Ended			9 Months Ended
	Dec. 31, 2022 USD ($)	Nov. 30, 2023 USD ($)	Nov. 30, 2022 USD ($)	May 31, 2022 USD ($)	Nov. 30, 2023 USD ($)	Nov. 30, 2022 USD ($)	Dec. 23, 2021 renewal
Commitments and contingencies
Number of other companies named in litigation | renewal							5
Proceeds from insurance settlement	$ 11,500		$ 34,500
Gain from insurance recoveries			9,700
Weather-Related Incident
Commitments and contingencies
Weather related inventory write-down				$ 34,400
Probable insurance recoveries				34,400
Health & Wellness
Commitments and contingencies
Charge to write off obsolete packaging		$ 0	2,103		$ 0	$ 22,101
Health & Wellness | Cost of Sales
Commitments and contingencies
Charge to write off obsolete packaging		0	370		0	16,928
Health & Wellness | Cost of Sales | Obsolete Packaging
Commitments and contingencies
Charge to write off obsolete packaging				$ 4,400
Health & Wellness | SG&A
Commitments and contingencies
Charge to write off obsolete packaging		$ 0	$ 1,733		$ 0	$ 5,173

Long-Term Debt - Schedule (Deta

Long-Term Debt - Schedule (Details) - USD ($) $ in Thousands	Nov. 30, 2023	Feb. 28, 2023
Long-term debt
Unamortized prepaid financing fees	$ (1,540)	$ (2,463)
Total long-term debt	735,648	934,412
Less: current maturities of long-term debt	(6,235)	(6,064)
Long-term debt, excluding current maturities	$ 729,413	$ 928,348
Line of credit
Long-term debt
Weighted average effective interest rate	7.10%	6.60%
Line of credit | Credit Agreement
Long-term debt
Aggregate principal balance	$ 737,188	$ 936,875
Line of credit | Credit Agreement | Revolving loans
Long-term debt
Aggregate principal balance	495,000	690,000
Line of credit | Credit Agreement | Term loans
Long-term debt
Aggregate principal balance	$ 242,188	$ 246,875

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022	Feb. 28, 2023
Debt Instrument [Line Items]
Interest costs incurred		$ 12,900	$ 14,800	$ 41,500	$ 30,000
Interest costs capitalized		0	$ 1,700	900	$ 3,300
Revolving loans
Debt Instrument [Line Items]
Maximum revolving commitment		1,250,000		1,250,000
Line of credit
Debt Instrument [Line Items]
Fixed rate debt		625,000		625,000		$ 425,000
Maximum additional debt allowed under debt covenants		336,200		336,200
Maximum additional debt allowed in the event a qualified acquisition is consummated		569,600		$ 569,600
Line of credit | Minimum | Base rate
Debt Instrument [Line Items]
Margin (as a percent)				0%
Line of credit | Minimum | SOFR
Debt Instrument [Line Items]
Margin (as a percent)				1%
Line of credit | Maximum | Base rate
Debt Instrument [Line Items]
Margin (as a percent)				1%
Line of credit | Maximum | SOFR
Debt Instrument [Line Items]
Margin (as a percent)				2%
Line of credit | Credit Agreement | SOFR
Debt Instrument [Line Items]
Additional credit spread				0.10%
Line of credit | Letter of credit
Debt Instrument [Line Items]
Amount outstanding, letters of credit		15,500		$ 15,500
Line of credit | Revolving loans | Credit Agreement
Debt Instrument [Line Items]
Maximum allowable increase due to accordion feature				300,000
Proceeds from exercise of accordion feature	$ 250,000
Percent of term loans due quarterly	0.625%
Fixed rate debt						$ 425,000
Amount available for borrowings		$ 739,500		$ 739,500

Fair Value - Summary of Financi

Fair Value - Summary of Financial Assets and Liabilities (Details) - Recurring - Fair Values - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	Nov. 30, 2023	Feb. 28, 2023
Assets:
Cash equivalents (money market accounts)	$ 2,829	$ 381
Total assets	13,585	7,550
Liabilities:
Total liabilities	699	711
Interest rate swaps
Assets:
Derivative assets	3,117	5,746
Foreign currency derivatives
Assets:
Derivative assets	204	1,423
Liabilities:
Derivative liabilities	699	711
US Treasury Bill Securities
Assets:
U.S. Treasury Bills	$ 7,435	$ 0

Fair Value - Narrative (Details

Fair Value - Narrative (Details) - US Treasury Bill Securities $ in Thousands	3 Months Ended
	Nov. 30, 2023 USD ($)
Fair Value
Interest income on US Treasury bills	$ 100
Minimum
Fair Value
Term of US treasury bills held to maturity	1 year
Maximum
Fair Value
Term of US treasury bills held to maturity	3 years
Prepaid Expenses and Other Current Assets
Fair Value
US treasury bills, carrying value, current	$ 2,400
Other Assets
Fair Value
US treasury bills, carrying value, non-current	$ 5,000

Financial Instruments and Ris_3

Financial Instruments and Risk Management - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022	Feb. 28, 2023
Foreign currency derivatives | Cash flow hedges
Foreign Currency Risk and Currency Exchange Uncertainties
Net gain reported in AOCI to be reclassified			$ (1,600)
Period of reclassification to AOCI			12 months
Credit agreement
Foreign Currency Risk and Currency Exchange Uncertainties
Fixed rate debt	$ 625,000		$ 625,000		$ 425,000
Credit agreement | Credit Agreement
Foreign Currency Risk and Currency Exchange Uncertainties
Aggregate principal balance	737,188		737,188		$ 936,875
SG&A
Foreign Currency Risk and Currency Exchange Uncertainties
Net foreign exchange gains (losses), including the impact of currency hedges and currency swaps	$ 100	$ 1,100	$ (300)	$ (1,400)
Net sales revenue | Geographic concentration | International operations - transactions denominated in foreign currencies
Foreign Currency Risk and Currency Exchange Uncertainties
Concentration risk percentage		15%	14%	13%

Financial Instruments and Ris_4

Financial Instruments and Risk Management - Derivative FV (Details) € in Thousands, £ in Thousands, kr in Thousands, $ in Thousands, $ in Thousands	Nov. 30, 2023 EUR (€)	Nov. 30, 2023 USD ($)	Nov. 30, 2023 CAD ($)	Nov. 30, 2023 GBP (£)	Nov. 30, 2023 NOK (kr)	Feb. 28, 2023 EUR (€)	Feb. 28, 2023 USD ($)	Feb. 28, 2023 CAD ($)	Feb. 28, 2023 GBP (£)	Feb. 28, 2023 NOK (kr)
Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		$ 2,148					$ 5,353
Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		1,173					1,816
Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		642					711
Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		57					0
Derivatives designated as hedging instruments | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		2,148					5,345
Derivatives designated as hedging instruments | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		1,173					1,816
Derivatives designated as hedging instruments | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		578					711
Derivatives designated as hedging instruments | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		57					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount | €	€ 32,000					€ 29,310
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					257
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		44					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		104					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount			$ 22,250					$ 30,000
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		103					962
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		18					11
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		4					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount | £				£ 26,760					£ 19,400
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		474					711
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		53					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount | kr					kr 5,000					kr 40,000
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		39					185
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Interest rate swaps
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount		625,000					425,000
Derivatives designated as hedging instruments | Interest rate swaps | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		2,006					3,941
Derivatives designated as hedging instruments | Interest rate swaps | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		1,111					1,805
Derivatives designated as hedging instruments | Interest rate swaps | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Interest rate swaps | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives not designated under hedge accounting | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					8
Derivatives not designated under hedge accounting | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		64					0
Derivatives not designated under hedge accounting | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets							6
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets							0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities							0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities							0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets							2
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets							0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities							0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities							$ 0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount | €	€ 740					€ 500
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		14
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount | £				£ 1,400					£ 400
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		50
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		$ 0

Financial Instruments and Ris_5

Financial Instruments and Risk Management - Derivative Tax Effect (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	$ 286	$ 786	$ 2,050	$ 12,960
Gain (Loss) Reclassified from AOCI into Income	2,425	4,652	5,814	7,602
Gain (Loss)  Recognized in Income	(225)	(12)	(265)	613
Foreign currency derivatives | Cash flow hedges
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	278	(685)	(968)	7,860
Foreign currency derivatives | Cash flow hedges | SG&A
Pre-tax effect of derivative instruments
Gain (Loss) Reclassified from AOCI into Income	212	4,484	167	8,395
Interest rate swaps | Cash flow hedges
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	8	1,471	3,018	5,100
Interest rate swaps | Cash flow hedges | Interest expense
Pre-tax effect of derivative instruments
Gain (Loss) Reclassified from AOCI into Income	2,213	168	5,647	(793)
Cross currency debt swaps | SG&A
Pre-tax effect of derivative instruments
Gain (Loss)  Recognized in Income	0	0	0	875
Forward contracts | SG&A
Pre-tax effect of derivative instruments
Gain (Loss)  Recognized in Income	$ (225)	$ (12)	$ (265)	$ (262)

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Nov. 30, 2023	Aug. 31, 2023	May 31, 2023	Nov. 30, 2022	Aug. 31, 2022	May 31, 2022	Nov. 30, 2023	Nov. 30, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 1,501,883	$ 1,514,908	$ 1,488,811	$ 1,398,346	$ 1,356,422	$ 1,327,339	$ 1,488,811	$ 1,327,339
Other comprehensive income (loss) before reclassification							2,050	12,960
Amounts reclassified out of AOCI							(5,814)	(7,602)
Tax effects							875	(1,421)
Total other comprehensive (loss) income, net of tax	(1,628)	2,454	(3,715)	(3,061)	3,839	3,159	(2,889)	3,937
Ending balance	1,586,278	1,501,883	1,514,908	1,457,073	1,398,346	1,356,422	1,586,278	1,457,073
Interest Rate Swaps
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			4,394			(2,126)	4,394	(2,126)
Other comprehensive income (loss) before reclassification							3,018	5,100
Amounts reclassified out of AOCI							(5,647)	793
Tax effects							619	(1,391)
Total other comprehensive (loss) income, net of tax							(2,010)	4,502
Ending balance	2,384			2,376			2,384	2,376
Foreign Currency Contracts
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			553			2,328	553	2,328
Other comprehensive income (loss) before reclassification							(968)	7,860
Amounts reclassified out of AOCI							(167)	(8,395)
Tax effects							256	(30)
Total other comprehensive (loss) income, net of tax							(879)	(565)
Ending balance	(326)			1,763			(326)	1,763
Total
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	3,686	1,232	4,947	7,200	3,361	202	4,947	202
Total other comprehensive (loss) income, net of tax	(1,628)	2,454	(3,715)	(3,061)	3,839	3,159
Ending balance	$ 2,058	$ 3,686	$ 1,232	$ 4,139	$ 7,200	$ 3,361	$ 2,058	$ 4,139

Segment Information - Segment I

Segment Information - Segment Information by Segment (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2023 USD ($) segment	Nov. 30, 2022 USD ($)	Nov. 30, 2023 USD ($) segment	Nov. 30, 2022 USD ($)
Segment information
Number of segments | segment	2		2
Sales revenue, net	$ 549,614	$ 558,606	$ 1,515,849	$ 1,588,084
Restructuring charges	3,890	10,463	14,862	15,241
Operating income	106,927	77,193	194,413	158,078
Capital and intangible asset expenditures	9,124	33,559	29,681	146,194
Depreciation and amortization	12,431	11,713	37,037	33,330
Home & Outdoor
Segment information
Sales revenue, net	235,948	228,937	693,069	703,759
Restructuring charges	583	5,090	4,644	5,562
Operating income	49,514	30,847	107,729	102,722
Capital and intangible asset expenditures	7,674	28,788	23,513	133,939
Depreciation and amortization	6,025	4,716	17,033	13,704
Beauty & Wellness
Segment information
Sales revenue, net	313,666	329,669	822,780	884,325
Restructuring charges	3,307	5,373	10,218	9,679
Operating income	57,413	46,346	86,684	55,356
Capital and intangible asset expenditures	1,450	4,771	6,168	12,255
Depreciation and amortization	$ 6,406	$ 6,997	$ 20,004	$ 19,626

Segment Information - Revenue b

Segment Information - Revenue by Domestic and International (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022
Segment information
Sales revenue, net	$ 549,614	$ 558,606	$ 1,515,849	$ 1,588,084
Domestic sales revenue, net
Segment information
Sales revenue, net	428,582	437,894	1,176,190	1,254,545
International sales revenue, net
Segment information
Sales revenue, net	$ 121,032	$ 120,712	$ 339,659	$ 333,539
Revenue from Contract with Customer Benchmark | Geographic concentration
Segment information
Concentration risk percentage	100%	100%	100%	100%
Revenue from Contract with Customer Benchmark | Geographic concentration | Domestic sales revenue, net
Segment information
Concentration risk percentage	78%	78.40%	77.60%	79%
Revenue from Contract with Customer Benchmark | Geographic concentration | International sales revenue, net
Segment information
Concentration risk percentage	22%	21.60%	22.40%	21%

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022
Income Tax Disclosure [Abstract]
Income tax expense (benefit) as a percent of income before income taxes	19.50%	19.10%	18.40%	18.60%

Earnings per Share (Details)

Earnings per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Nov. 30, 2022
Weighted average diluted securities
Weighted average shares outstanding, basic (in shares)	23,743	23,991	23,903	23,942
Incremental shares from share-based payment arrangements (in shares)	70	87	93	144
Weighted average shares outstanding, diluted (in shares)	23,813	24,078	23,996	24,086
Anti-dilutive securities
Weighted average diluted securities
Antidilutive securities (in shares)	9	53	57	45